The Essentials of FFP Dosing and Monitoring – ICHCC
Iranian Comprehensive Hemophilia Care Center (ICHCC) shared a post on LinkedIn:
“Maximum Safe Volume of Fresh Frozen Plasma (FFP): How Much Is Too Much?
Fresh Frozen Plasma (FFP) is an essential blood component used to replace multiple coagulation factors in patients with bleeding or significant coagulation abnormalities.
However, excessive or rapid plasma transfusion can lead to serious complications, particularly Transfusion-Associated Circulatory Overload (TACO).
What Is the Recommended Dose?
The standard therapeutic dose of FFP is:
- 10–15 mL/kg
This dose is usually sufficient to increase coagulation factor levels and improve hemostasis.
In selected situations, such as massive bleeding or severe coagulation factor deficiencies, doses up to:
- 20 mL/kg
May be required, provided the patient is carefully monitored.
Higher doses generally offer little additional correction of coagulation tests while substantially increasing the risk of volume overload.
- In Children
Standard dose: 10–15 mL/kg
The maximum recommended single dose is generally 20 mL/kg, reserved for carefully selected patients with close clinical monitoring.
Infants, neonates, and children with cardiac or renal disease require slower infusion rates and meticulous observation during transfusion.
- In Adults
For a 70-kg adult, the usual therapeutic dose is:
700–1,050 mL (approximately 3–4 units of FFP)
If larger volumes are required, patients should be closely monitored for signs of:
- Transfusion-Associated Circulatory Overload (TACO)
- Pulmonary edema
- Heart failure
- Hypertension
- Respiratory distress
Who Is at Highest Risk for TACO?
- Elderly patients
- Neonates and infants
- Patients with heart failure
- Chronic kidney disease
- Hypoalbuminemia
Patients receiving multiple blood components
- How Can We Reduce the Risk?
- Calculate the dose based on body weight.
- Infuse more slowly in high-risk patients.
- Monitor blood pressure, oxygen saturation, respiratory status, and fluid balance.
- Consider diuretics (e.g., furosemide) in selected high-risk patients when clinically appropriate.
Clinical Pearl
FFP should not be transfused simply to correct a mildly elevated INR or abnormal coagulation tests in the absence of bleeding or an invasive procedure.
Appropriate indications, weight-based dosing (10–15 mL/kg), and careful monitoring are the keys to maximizing benefit while minimizing transfusion-related complications such as TACO.”

Stay updated with Hemostasis Today.
-
Nov 6, 2026, 22:54Vincenzo De Angelis: Presenting Trends and Challenges in Blood and Plasma Collection and Use in Europe
-
Nov 6, 2026, 22:50Alexis Caulier: Leveraging Epigenetic Silencing in HSCs to Modulate Platelet Aggregation
-
Nov 6, 2026, 22:40Panama Achieves Self-Sufficiency in Haemophilia Care – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Nov 6, 2026, 22:31Luisa Weiss: Exploring the Role of Platelets and Extracellular Vesicles in Calcific Aortic Valve Disease
-
Nov 6, 2026, 22:29Nour Al-Mozain: The Role of Therapeutic Apheresis and Cell Therapy in Advancing Regional Practice
-
Nov 6, 2026, 22:28Moazzam Shahzad: Celebrating Mentees Receiving the 2026 ASH Abstract Achievement Award
-
Nov 6, 2026, 22:25Habib Bennaceur: Self-Sufficiency in Haemophilia Care – A Major Achievement for Panama
-
Nov 6, 2026, 22:25Alessandro Lucchesi: Engineering Disease Trajectories in Myeloproliferative Neoplasms at RiseMPN 2026
-
Nov 6, 2026, 22:24Davood Bava: A New Practical Handbook for Advances in Transfusion Medicine